Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention

Acta Diabetologica

Volumn 52, Issue 3, 2015, Pages 473-481

  Elding Larsson, Helena ^a   Larsson, Christer ^b   Lernmark, Åke ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Dysglycemia; First phase insulin response; IA 2A; Impaired glucose metabolism; Intravenous glucose tolerance tests; Oral glucose tolerance test; Prediction; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; INSULIN; INSULINOMA ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8; BIOLOGICAL MARKER; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GLYCOSYLATED HEMOGLOBIN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ADOLESCENT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DYSGLYCEMIA; FEMALE; GENOTYPE; GLUCOSE METABOLISM; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ONSET AGE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCREENING; SECONDARY PREVENTION; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; AUTOANTIBODIES; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; RISK FACTORS; SECONDARY PREVENTION;

EID: 84930092396     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0680-1     Document Type: Article

References (26)

1. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–2479. doi:10.1001/jama.2013.6285
2. Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55(7):1926–1936. doi:10.1007/s00125-012-2523-3
3. Salminen K, Sadeharju K, Lonnrot M, Vahasalo P, Kupila A, Korhonen S, Ilonen J, Simell O, Knip M, Hyoty H (2003) Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol 69(1):91–98. doi:10.1002/jmv.10260
4. Lonnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, Savola K, Muona P, Simell T, Koskela P, Hyoty H (2000) Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 49(8):1314–1318
5. Kondrashova A, Hyoty H (2014) Role of viruses and other microbes in the pathogenesis of type 1 diabetes. Int Rev Immunol 33(4):284–295. doi:10.3109/08830185.2014.889130
6. Chmiel R, Beyerlein A, Knopff A, Hummel S, Ziegler AG, Winkler C (2014) Early infant feeding and risk of developing islet autoimmunity and type 1 diabetes. Acta Diabetol. doi:10.1007/s00592-014-0628-5
7. Eringsmark Regnell S, Lernmark A (2013) The environment and the origins of islet autoimmunity and Type 1 diabetes. Diabet Med 30(2):155–160. doi:10.1111/dme.12099
8. Beyerlein A, Thiering E, Pflueger M, Bidlingmaier M, Stock J, Knopff A, Winkler C, Heinrich J, Ziegler AG (2014) Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children. Pediatr Diabetes 15(7):534–542. doi:10.1111/pedi.12118
9. Cubas-Duenas I, Cabrera-Rode E, Sarmiento L, Molina G, Fonseca M, Arranz C, Dominguez E, Gonzalez P, Vera M, Diaz-Horta O (2013) First-degree relatives of persons with type 1 diabetes: insulin resistance and enterovirus infection are associated with different patterns of islet cell autoimmunity. Acta Diabetol 50(2):233–239. doi:10.1007/s00592-011-0297-6
10. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG (2004) Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 140(11):882–886
11. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G, Diabetes Prevention Trial-Type 1 Study G (2009) Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32(12):2269–2274. doi:10.2337/dc09-0934
12. Stene LC, Barriga K, Hoffman M, Kean J, Klingensmith G, Norris JM, Erlich HA, Eisenbarth GS, Rewers M (2006) Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatric diabetes 7(5):247–253. doi:10.1111/j.1399-5448.2006.00198.x
13. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS, Diabetes Prevention Trial-Type 1 Study G (2009) Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 32(9):1603–1607. doi:10.2337/dc08-2140
14. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS (2006) Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29(3):643–649
15. Siljander HT, Hermann R, Hekkala A, Lähde J, Tanner L, Keskinen P, Ilonen J, Simell O, Veijola R, Knip M (2013) Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced β-cell autoimmunity. Eur J Endocrinol 169(4):479–485. doi:10.1530/EJE-13-0206
16. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, Group TDTS, Group DPT-TS (2012) The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care 35(7):1552–1555. doi:10.2337/dc12-0011
17. American Diabetes A (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl 1):S81–S90. doi:10.2337/dc14-S081
18. Andersson C, Carlsson A, Cilio C, Cedervall E, Ivarsson SA, Jonsdottir B, Jonsson B, Larsson K, Neiderud J, Lernmark A, Elding Larsson H, Di A-ITSG (2013) Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study. Pediatr Diabetes 14(5):341–349. doi:10.1111/pedi.12023
19. Ranke MB (2003) Diagnostics of endocrine function in children and adolescents. In: Karger (Ed), 3rd revised and extended edition
20. Andersson C, Larsson K, Vaziri-Sani F, Lynch K, Carlsson A, Cedervall E, Jonsson B, Neiderud J, Mansson M, Nilsson A, Lernmark A, Elding Larsson H, Ivarsson SA (2011) The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 44(5):394–405. doi:10.3109/08916934.2010.540604
21. Karlberg J, Luo ZC, Albertsson-Wikland K (2001) Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr 90(12):1427–1434
22. Elding Larsson H, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark A, Rewers M, Simell O, She JX, Ziegler A, Haller MJ, Group tTS (2013) Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes. doi:10.1111/pedi.12066
23. Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, Groups TDTaDPTTS (2013) Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes 62(12):4179–4183. doi:10.2337/db13-0656
24. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, Type 1 Diabetes TrialNet Study G, Diabetes Prevention Trial-Type 1 Study G (2013) The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 36(9):2615–2620. doi:10.2337/dc13-0425
25. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Groups DPTTaTDTS (2011) A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 34(11):2435–2437. doi:10.2337/dc11-0981
26. Decochez K, Truyen I, van der Auwera B, Weets I, Vandemeulebroucke E, de Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Pipeleers DG, Gorus FK, Belgian Diabetes R (2005) Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 48(4):687–694. doi:10.1007/s00125-005-1702-x